Chiromics LLC and Bristol-Myers Squibb have entered into strategic research alliance to discover and optimize novel classes of small molecules against multiple therapeutic targets. The collaboration includes non-exclusive license to Chiromics’ chemical compound library and an exclusive license to a chemical compound collection.   Chiromics’ chemical compound collection and Chalis, the company’s hit recognition algorithm for affinity selection, will be used for the identification of new lead mole...